YENİ TANI MULTİPL MYELOMLU HASTALARDA OTOLOG PERİFERİK HEMATOPOETİK KÖK HÜCRE TRANSPLANTASYONU: 32 HASTA İLE TEK MERKEZ DENEYİMİ

Cilt: 42 Sayı: 3 1 Eylül 2003
  • Seçkin Çağırgan
  • Mustafa Pehlivan
  • Ayhan Dönmez
Ege Tıp Dergisi Kapak
Ege Tıp Dergisi
PDF İndir
EN TR

AUTOLOGOUS PERIPHERAL BLOOD HEMATOPOIETIC STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A SINGLE CENTER EXPERIENCE WITH 32 PATIENTS

Abstract

In this study, the effect of autologous peripheral blood hematopoietic stem celi transplantation (APBSCT) on the survival of 32 multiple myeloma (MM) patients. After VAD chemotherapy to reduce the tumor burden, ali patients exceptone are mobilized by cyclophosphamide (2-4 g/m2)+ growth factor. Transplantation related mortality was 9.3% (n=3). Total response was 93.4% with 13 patients in complete remission (40.6%) and 17 patients in partial response (53.1%) after transplantation. In the follow-up period of median 27.6 months, it has not been reached to median overall survival, but overall survival probability in 5 years is 61%, and median event-free survival (EFS) was 25 months. EFS in 4 years was found to be 36.1%. These results suggest that APBSCT in newly diagnosed MM patients, give a high response and are in correlation with the studies demonstrating that APBSCT lengthens the overall survival significantly.

Keywords

Ayrıntılar

Birincil Dil

Türkçe

Konular

-

Bölüm

-

Yazarlar

Seçkin Çağırgan

Mustafa Pehlivan

Ayhan Dönmez

Yayımlanma Tarihi

1 Eylül 2003

Gönderilme Tarihi

1 Eylül 2003

Kabul Tarihi

-

Yayımlandığı Sayı

Yıl 2003 Cilt: 42 Sayı: 3

IZ

https://izlik.org/JA55JR69ZG

Kaynak Göster

RIS / Bibtex
Vancouver
1.Seçkin Çağırgan, Mustafa Pehlivan, Ayhan Dönmez. YENİ TANI MULTİPL MYELOMLU HASTALARDA OTOLOG PERİFERİK HEMATOPOETİK KÖK HÜCRE TRANSPLANTASYONU: 32 HASTA İLE TEK MERKEZ DENEYİMİ. ETD [Internet]. 01 Eylül 2003;42(3):167-72. Erişim adresi: https://izlik.org/JA55JR69ZG

Ege Tıp Dergisi, makalelerin Atıf-Gayri Ticari-Aynı Lisansla Paylaş 4.0 Uluslararası (CC BY-NC-SA 4.0) lisansına uygun bir şekilde paylaşılmasına izin verir.